Eli Lilly has determined its monoclonal antibody treatment reduces patients' COVID-19 viral load and helps them avoid hospitalization, it announced Wednesday.
The treatment involves combining two antibodies and injecting them into patients — similar to the treatment developed by Regeneron that President Trump received. Less than 1 percent of patients sick with COVID-19 and injected with the treatment went to the hospital, compared to 5.8 percent who had a placebo, Eli Lilly's study found. And at the end of 11 days, the antibody combination "significantly reduced" the amount of virus found in patients' nasal swabs.
Last month, the pharmaceutical company also announced positive results from a trial involving just one antibody. Eli Lilly is now seeking the Food and Drug Administration's emergency use authorization for the single antibody treatment. It will likely seek authorization for the combination therapy next month, after it manufactures a bigger supply and gets patients into clinical trials.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Wednesday's news sent Eli Lilly's shares up more than 3 percent in morning trading.
-
An introvert's dream? Flu camps that offer £4,400 to spend two weeks aloneUnder The Radar A fortnight in isolation may not be as blissful as it sounds
-
Can Trump put his tariffs on stronger legal footing?Today's Big Question Appeals court says 'emergency' tariffs are improper
-
Film reviews: The Roses, Splitsville, and TwinlessFeature A happy union devolves into domestic warfare, a couple's open marriage reaps chaos, and an unlikely friendship takes surprising turns
-
New York court tosses Trump's $500M fraud fineSpeed Read A divided appeals court threw out a hefty penalty against President Trump for fraudulently inflating his wealth
-
Trump said to seek government stake in IntelSpeed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting
-
US to take 15% cut of AI chip sales to ChinaSpeed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with DisneySpeed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
-
Samsung to make Tesla chips in $16.5B dealSpeed Read Tesla has signed a deal to get its next-generation chips from Samsung
-
FCC greenlights $8B Paramount-Skydance mergerSpeed Read The Federal Communications Commission will allow Paramount to merge with the Hollywood studio Skydance
-
Tesla reports plummeting profitsSpeed Read The company may soon face more problems with the expiration of federal electric vehicle tax credits
-
Dollar faces historic slump as stocks hit new highSpeed Read While stocks have recovered post-Trump tariffs, the dollar has weakened more than 10% this year
